Australia's Vitrafy Life Sciences hits record low on interim loss
** Shares of Vitrafy Life Sciences VFY.AX fall 6.6% to a
record low of A$1.52
** Biomedical firm posts interim loss of A$25.7 mln ($16.15
mln) in its first earnings report since its IPO in late November
vs loss of A$46,709 a year earlier
** Stock posts its biggest intraday pct loss since January
14
** Stock down 5.9% YTD, including current session moves
($1 = 1.5916 Australian dollars)
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
Recent news on Vitrafy Life Sciences
See all newsBrief: Vitrafy Life Sciences Appoints Jan Gielen As CFO
Australia's Vitrafy Life Sciences heads for best day in 2 months on Versiti deal
Australia's Vitrafy Life Sciences gains on entering US market
Brief: Vitrafy Life Sciences Enters U.S. Cell & Gene Therapy Market With Charter Medical Agreement
Brief: Vitrafy Life Sciences Posts FY Operating Loss Of A$14.6 Million